| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Galapagos NV (AS: GLPG)
GLPG Technical Analysis
5
| As on 19th Sep 2025 GLPG SHARE Price closed @ 28.80 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 25.23 & Strong Buy for SHORT-TERM with Stoploss of 25.74 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GLPGSHARE Price
| Open | 27.88 | Change | Price | % |
| High | 29.12 | 1 Day | 0.92 | 3.30 |
| Low | 27.74 | 1 Week | 1.10 | 3.97 |
| Close | 28.80 | 1 Month | 0.80 | 2.86 |
| Volume | 256816 | 1 Year | 1.10 | 3.97 |
| 52 Week High 28.94 | 52 Week Low 21.02 | ||||
AS Netherlands Most Active Stocks
| RDSA | 22.80 | -1.08% |
| PHARM | 1.25 | 5.04% |
| INGA | 21.64 | 0.74% |
| KPN | 4.12 | 0.73% |
| AGN | 6.68 | 1.67% |
| PRX | 56.93 | 0.67% |
| UMG | 23.52 | -3.88% |
| ABN | 25.79 | -0.04% |
| AD | 33.78 | 0.18% |
| PHIA | 23.86 | -0.21% |
AS Netherlands Top Gainers Stocks
AS Netherlands Top Losers Stocks
| GLPG Daily Charts |
GLPG Intraday Charts |
Whats New @ Bazaartrend |
GLPG Free Analysis |
|
|
GLPG Important Levels Intraday
| RESISTANCE | 31.46 |
| RESISTANCE | 30.61 |
| RESISTANCE | 30.08 |
| RESISTANCE | 29.55 |
| SUPPORT | 28.05 |
| SUPPORT | 27.52 |
| SUPPORT | 26.99 |
| SUPPORT | 26.14 |
GLPG Forecast September 2025
| 4th UP Forecast | 38.01 |
| 3rd UP Forecast | 35.06 |
| 2nd UP Forecast | 33.23 |
| 1st UP Forecast | 31.41 |
| 1st DOWN Forecast | 26.19 |
| 2nd DOWN Forecast | 24.37 |
| 3rd DOWN Forecast | 22.54 |
| 4th DOWN Forecast | 19.59 |
GLPG Weekly Forecast
| 4th UP Forecast | 31.46 |
| 3rd UP Forecast | 30.61 |
| 2nd UP Forecast | 30.08 |
| 1st UP Forecast | 29.55 |
| 1st DOWN Forecast | 28.05 |
| 2nd DOWN Forecast | 27.52 |
| 3rd DOWN Forecast | 26.99 |
| 4th DOWN Forecast | 26.14 |
GLPG Forecast2025
| 4th UP Forecast | 50.15 |
| 3rd UP Forecast | 43.3 |
| 2nd UP Forecast | 39.07 |
| 1st UP Forecast | 34.84 |
| 1st DOWN Forecast | 22.76 |
| 2nd DOWN Forecast | 18.53 |
| 3rd DOWN Forecast | 14.3 |
| 4th DOWN Forecast | 7.45 |
Galapagos NV ( AS Netherlands Symbol : GLPG )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GLPG Business Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service